Multiple sclerosis in the elderly: a retrospective cohort study

• Published in: Journal of neurology 2024-02, Vol.271 (2), p.674-687
• Main Authors: Zinganell, Anne, Göbel, Georg, Berek, Klaus, Hofer, Barbara, Asenbaum-Nan, Susanne, Barang, Matin, Böck, Klaus, Bsteh, Christian, Bsteh, Gabriel, Eger, Stephan, Eggers, Christian, Fertl, Elisabeth, Joldic, Damir, Khalil, Michael, Langenscheidt, Dieter, Komposch, Martina, Kornek, Barbara, Kraus, Jörg, Krendl, Reinhard, Rauschka, Helmut, Sellner, Johann, Auer, Michael, Hegen, Harald, Pauli, Franziska Di, Deisenhammer, Florian
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cerebellum; Clinical trials; Comorbidity; Dementia disorders; Diagnosis; Disease Progression; Epilepsy; Female; Humans; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Multiple sclerosis; Multiple Sclerosis - diagnosis; Multiple Sclerosis - epidemiology; Multiple Sclerosis - therapy; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Neurology; Neuroradiology; Neurosciences; Original Communication; Prognosis; Recurrence; Retrospective Studies; Risk factors
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-023-12041-1

Background There is a lack of knowledge of disease course, prognosis, comorbidities and potential treatments of elderly MS patients. Objective To characterize the disease course including disability progression and relapses, to quantify the use of DMTs and to identify comorbidities and risk factors for progression in elderly multiple sclerosis (MS) patients. Methods This is a retrospective study of 1200 Austrian MS patients older than 55 years as of May 1st, 2017 representing roughly one-third of all the MS patients of this age in Austria. Data were collected from 15 MS centers including demographics, first symptom at onset, number of relapses, evolvement of disability, medication, and comorbidities. Results Median observation time was 17.1 years with 957 (80%) relapsing and 243 (20%) progressive onsets. Average age at diagnosis was 45 years with a female predominance of 71%. Three-hundred and twenty-six (27%) patients were never treated with a DMT, while most treated patients received interferons (496; 41%) at some point. At last follow-up, 420 (35%) patients were still treated with a DMT. No difference was found between treated and never-treated patients in terms of clinical outcome; however, patients with worse disability progression had significantly more DMT switches. Pyramidal onset, number of comorbidities, dementia, epilepsy, and psychiatric conditions as well as a higher number of relapses were associated with worse outcome. The risk of reaching EDSS 6 rose with every additional comorbidity by 22%. In late and very-late-onset MS (LOMS, VLOMS) time to diagnosis took nearly twice the time compared to adult and early onset (AEOMS). The overall annualized relapse rate (ARR) decreased over time and patients with AEOMS had significantly higher ARR compared to LOMS and VLOMS. Four percent of MS patients had five medications or more fulfilling criteria of polypharmacy and 20% of psychiatric drugs were administered without a matching diagnosis. Conclusions In this study, we identified number of comorbidities, pyramidal and cerebellar signs, and a higher number of relapses as unfavorable prognostic factors in elderly MS patients filling gaps of knowledge in patients usually underrepresented in clinical trials and may guide future therapeutic studies.